Skip to main content
SpringerLink
Log in

Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?

  • Practice Point
  • Published:

From Nature Clinical Practice Oncology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Tannock IF et al. (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomised trial with palliative end points. J Clin Oncol 14: 1756–1764

    Article  CAS  Google Scholar 

  2. Kantoff W et al. (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukaemia group B 9182 study. J Clin Oncol 17: 2506–2513

    Article  CAS  Google Scholar 

  3. Berry W et al. (2002) Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 168: 2439–2443

    Article  CAS  Google Scholar 

  4. Muthuramalingam SR et al. (2004) Management of patients with hormone refractory prostate cancer. Clin Oncol 16: 505–516

    Article  CAS  Google Scholar 

  5. Oudard S et al. (2002) Preliminary results of a phase II randomised trial of docetaxel (D), estramustine (E) and prednisone (P) – two schedules – versus mitoxantrone (M) and prednisone in patients (pts) with hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 21: a706

    Google Scholar 

  6. Petrylak DP et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513–1520

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Suzanne Farley, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Consultant Medical Oncologist at the Cancer Research UK Department of Medical Oncology at the Churchill Hospital, Oxford

    Andrew Protheroe

Authors
  1. Andrew Protheroe
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Protheroe, A. Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?. Nat Rev Clin Oncol 2, 68–69 (2005). https://doi.org/10.1038/ncponc0080

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0080

  • Springer Nature Limited

Search

Navigation